Bristol-Myers Squibb EPS - Earnings per Share 2006-2019 | BMY

Bristol-Myers Squibb annual and quarterly earnings per share history from 2006 to 2019. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Bristol-Myers Squibb EPS for the quarter ending September 30, 2019 was $0.83, a 28.45% decline year-over-year.
  • Bristol-Myers Squibb EPS for the twelve months ending September 30, 2019 was $3.45, a 283.33% increase year-over-year.
  • Bristol-Myers Squibb 2018 annual EPS was $3.01, a 393.44% increase from 2017.
  • Bristol-Myers Squibb 2017 annual EPS was $0.61, a 76.98% decline from 2016.
  • Bristol-Myers Squibb 2016 annual EPS was $2.65, a 184.95% increase from 2015.
Bristol-Myers Squibb Annual EPS
2018 $3.01
2017 $0.61
2016 $2.65
2015 $0.93
2014 $1.20
2013 $1.54
2012 $1.16
2011 $2.16
2010 $1.79
2009 $5.34
2008 $2.62
2007 $1.09
2006 $0.81
2005 $1.52
Bristol-Myers Squibb Quarterly EPS
Q3 2019 $0.83
Q2 2019 $0.87
Q1 2019 $1.04
Q4 2018 $0.71
Q3 2018 $1.16
Q2 2018 $0.23
Q1 2018 $0.91
Q4 2017 $-1.40
Q3 2017 $0.51
Q2 2017 $0.56
Q1 2017 $0.94
Q4 2016 $0.53
Q3 2016 $0.72
Q2 2016 $0.69
Q1 2016 $0.71
Q4 2015 $-0.12
Q3 2015 $0.42
Q2 2015 $-0.08
Q1 2015 $0.71
Q4 2014 $0.01
Q3 2014 $0.43
Q2 2014 $0.20
Q1 2014 $0.56
Q4 2013 $0.43
Q3 2013 $0.42
Q2 2013 $0.32
Q1 2013 $0.37
Q4 2012 $0.57
Q3 2012 $-0.43
Q2 2012 $0.38
Q1 2012 $0.64
Q4 2011 $0.51
Q3 2011 $0.56
Q2 2011 $0.52
Q1 2011 $0.57
Q4 2010 $0.28
Q3 2010 $0.55
Q2 2010 $0.53
Q1 2010 $0.43
Q4 2009 $4.05
Q3 2009 $0.48
Q2 2009 $0.49
Q1 2009 $0.32
Q4 2008 $0.63
Q3 2008 $1.28
Q2 2008 $0.38
Q1 2008 $0.33
Q4 2007 $-0.05
Q3 2007 $0.43
Q2 2007 $0.36
Q1 2007 $0.35
Q4 2006 $-0.06
Q3 2006 $0.17
Q2 2006 $0.34
Q1 2006 $0.36
Q4 2005 $0.26
Q3 2005 $0.49
Q2 2005 $0.50
Q1 2005 $0.27
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $99.843B $22.561B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $369.778B 16.02
Roche Holding AG (RHHBY) Switzerland $262.948B 0.00
Merck (MRK) United States $225.880B 17.50
Pfizer (PFE) United States $212.068B 12.60
Novartis AG (NVS) Switzerland $212.060B 17.90
Novo Nordisk (NVO) Denmark $134.242B 23.14
AbbVie (ABBV) United States $127.829B 10.02
AstraZeneca (AZN) United Kingdom $125.337B 22.64
Eli Lilly (LLY) United States $115.446B 21.32
GlaxoSmithKline (GSK) United Kingdom $113.811B 13.78
Sanofi (SNY) France $113.437B 13.94
Bayer (BAYRY) Germany $70.967B 10.51
H Lundbeck (HLUYY) Denmark $7.627B 11.01